The promise is continuous monitoring, catching deterioration before it becomes crisis. The reality is more complicated than the pitch decks. Here is an honest look at where the evidence is in 2026, what the technology actually delivers, and where the hype has gotten ahead of the data.
The hardware landscape has expanded dramatically. Continuous SpO2 monitoring is built into consumer smartwatches. Respiratory rate monitoring via accelerometry is standard in multiple wearable platforms. Smart inhalers with adherence tracking are commercially available for both COPD and asthma. Portable spirometers that sync to smartphone apps have been validated against laboratory-grade devices for home monitoring. The devices exist. The clinical integration does not — at least not consistently or well.
Consumer wearables show reasonable accuracy in studies of healthy adults at rest. Accuracy declines during exercise, with hypoxemia, with poor perfusion, and in patients with darker skin tones — documented repeatedly and representing a genuine equity concern the device industry has been slow to address. A 92% on a consumer smartwatch is not clinically equivalent to 92% on a calibrated pulse oximeter.
Inhaler adherence monitoring has been shown in multiple RCTs to improve adherence significantly compared to self-report. The clinical effect — reduction in exacerbations and emergency visits — follows from the adherence improvement. This is where the technology actually delivers on its promise.
CMS expanded RPM reimbursement significantly in 2023 and 2024. RT-driven RPM programs for COPD patients are now billable under CPT codes 99453, 99454, and 99457. The reimbursement funds dedicated RT time for remote monitoring work. Facilities that have not built RPM programs are leaving revenue on the table.
Wearable data generates noise. An RT managing a remote monitoring panel of 50 COPD patients will receive alerts that are mostly artifacts, position changes, device removal events, and measurement errors rather than clinical deteriorations. Programs that work have clear escalation protocols, alert thresholds calibrated to each patient's individual baseline, and dedicated RT time for data review.
“Wearable data is only as useful as the clinical workflow built around it. The technology does not manage patients. RTs manage patients. The technology gives RTs more data to work with — and more noise to filter.”
Last issue we covered the preparation. This issue is about what happens after you make the ask — the responses you are going to get, what each one actually means, and the specific moves that follow. Most RT salary guides stop at the ask. This is the part after.
This happens more often than RTs expect when the ask is anchored to market data and presented professionally. Accept without flinching. Do not express surprise. Say: “Thank you, I appreciate that — when will that be reflected in my next paycheck?” Then document it and share the outcome with RT colleagues who are afraid to ask.
The most common response at facilities with rigid pay bands. Pivot immediately to total compensation: shift differentials by specific dollar amount, CME and credentialing reimbursement cap, scheduling flexibility, professional development support. A $3,000 annual CME increase is worth more than a $1,500 salary increase after taxes.
A stall that often converts to yes with appropriate follow-up. Say: “Absolutely — when should I expect to hear back?” Get a specific date. If you do not hear back by that date, follow up once. If still no response, that is information about how this organization communicates.
A flat no tells you either the facility cannot pay market rates for your credentials, or it can and chooses not to. Neither is acceptable indefinitely. The appropriate response is to continue your job search with active intent. Update your resume. Contact recruiters. A no is not the end of the conversation. It is the beginning of your exit strategy.
The hospital with a rigid pay band might not offer you $5,000 more in base salary. That same hospital might easily offer $3,000 in additional CME reimbursement, a preferred scheduling block worth $2,000 in avoided costs, and credential exam reimbursement worth $800. That is $5,800 in additional annual value negotiated through channels the pay band does not control.
“Most RTs negotiate for the number on their paycheck and ignore the five other lines that add up to more than the number they were arguing about.”
Most critical care clinicians check serum magnesium — total magnesium. What most do not check is ionized magnesium, which is the biologically active fraction. Total serum magnesium can be normal while ionized magnesium is low — particularly in patients with hypoalbuminemia, which is extremely common in critically ill patients.
A normal total magnesium level in a critically ill patient with low albumin tells you very little about the patient's actual biologically available magnesium. Eumagnesemic hypomagnesemia — normal total magnesium, low ionized magnesium — is clinically relevant and frequently missed.
Why this matters for respiratory therapy specifically
Magnesium is a smooth muscle relaxant. Intravenous magnesium sulfate is a recognized adjunct therapy for severe acute asthma and refractory bronchospasm in intubated patients. An RT managing a patient with refractory bronchospasm not responding to standard bronchodilator therapy should consider whether ionized magnesium has been checked — not just total.
Magnesium is essential for normal neuromuscular junction function. Significant hypomagnesemia can impair respiratory muscle strength in ways that complicate ventilator weaning. A patient failing SBT despite apparent clinical readiness, with no other obvious explanation, is worth reviewing for electrolyte abnormalities including ionized magnesium.
The practical point for bedside RTs is not to order ionized magnesium independently. It is to know the value exists, know when it is clinically relevant, and ask the question in rounds when the clinical picture suggests it matters. “Has ionized magnesium been checked on this patient?” is a question that takes three seconds and occasionally changes management significantly.
40% Of ICU patients estimated to have some degree of magnesium deficiency | IV MgSO4 First-line adjunct for severe asthma not responding to bronchodilators alone | 2026 RT Magazine highlighted ionized magnesium in critical care monitoring this year |
Next: The AARC 2026 annual conference — what is on the agenda and what it means for your practice.
Soon: Neonatal transport RT — the most demanding subspecialty in respiratory therapy and how to pursue it.
On deck: Home ventilator management — the growing patient population most hospital RTs are underprepared to discharge.
Staying at the vent,
15 years across academic medical centers & community hospitals
